ARVINAS INC
ARVNNASDAQTrading Snapshot
- Day Range
- $7.46 – $7.59
- 52-Week Range
- $6.97 – $14.51
- Volume
- $2.77B
- Avg Volume
- $2.69B
- Shares Outstanding
- 64.5M
- Next Earnings
- Nov 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $263M
- Last Q Revenue
- $250M
- P/E Ratio
- 39.5
- P/S Ratio
- 1.5x
- EPS (TTM)
- $0.14
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −10.0%
Why Investors Own ARVN
- ✓High-growth profile — revenue up +26.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 70% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ARVINAS INC
ARVN
StockOtter · stockotter.spaceAbout ARVINAS INC
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate
– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,
Connor Clark & Lunn Investment Management Ltd. Invests $1.39 Million in Arvinas, Inc. $ARVN
Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Arvinas, Inc. (NASDAQ: ARVN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish
Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC platform. Despite Veppanu's approval for ESR1-mutated breast cancer, ARVN's share price remains near cash value, reflecting